Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia
Open Access
- 17 November 2015
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 29 (3) , 315-322
Abstract
Immunosuppression using everolimus (EVR) plus low‐dose tacrolimus (Tac) is commonly used in organ transplantation. EVR has potential antiviral effects. Herein, the long‐term outcomes and impacts of Tac‐EVR on the BK virus are reported in ABO‐incompatible kidney‐transplant recipients. The initial immunosuppressive regimen combined steroids, Tac, and mycophenolic acid (MPA). At a median of 141 (34–529) days post‐transplantation, seven stable ABO‐incompatible kidney‐transplant recipients were converted from MPA to EVR because of active BK replication, and compared with a reference group of fourteen ABO‐incompatible patients receiving classical Tac plus MPA. At 1 month before conversion, at 1, 3 months after, and at last follow‐up, clinical and biological parameters were monitored. The median time from conversion to the last follow‐up was 784 (398‐866) days. Conversion to EVR caused no change to rejection episodes or immunological status (isoagglutinin titers, anti‐HLA antibodies). At last follow‐up, median eGFR was similar in the Tac‐MPA versus Tac‐EVR group (40 [range: 14–56] vs. 54.5 ml/min/1.73 m2 [range: 0–128], P = 0.07). The major adverse event was dyslipidemia. Interestingly, conversion from MPA to EVR decreased BK viral load in five patients. ABO‐incompatible kidney‐transplant recipients with an active BK virus infection may benefit from conversion to EVR.Keywords
This publication has 23 references indexed in Scilit:
- BK Polyomavirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanismsReviews in Medical Virology, 2012
- Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantationTransplant International, 2012
- Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney TransplantationAmerican Journal of Transplantation, 2012
- Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experienceNephrology Dialysis Transplantation, 2011
- Everolimus and Minimization of Cyclosporine in Renal Transplantation: 24-Month Follow-Up of the EVEREST StudyTransplantation, 2011
- Low-Dose Calcineurin Inhibitor Regimen Combined With Mammalian Target of Rapamycin Inhibitors Preserves Kidney Functions in Renal Transplant Recipients Without Allograft NephropathyTransplantation Proceedings, 2010
- Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the ratNephrology Dialysis Transplantation, 2010
- Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12Biochemical Pharmacology, 2009
- Excellent Long-Term Results in De Novo Renal Transplant Recipients Treated With Proliferation Signal Inhibitors and Reduced Calcineurin Inhibitors ExposureTransplantation Proceedings, 2008